Priya Jayachandran, MD
Medical Oncology · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 1 carrier
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Hospitals listed: El Camino Health · USC Kenneth Norris Jr Cancer Hospital. That is not proof they admit you there this week.
Plans that list them
2 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Jayachandran’s office at (650) 988-8338 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence A127648 · Current
Licensed to practise in California · since 2013 · expires 2027-03-31 · University of Michigan Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$49,367
Medicare paid this office $49,367 for 136 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 85 | $32,153 | $113 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $3,144 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $2,934 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,061 | $103 |
| Hospital discharge day management, more than 30 minutes | 20 | $2,003 | $95 |
See all 6 services
| Long return visit (40+ min) | 85 | $32,153 | $113 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $3,144 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $2,934 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,061 | $103 |
| Hospital discharge day management, more than 30 minutes | 20 | $2,003 | $95 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 60 | $1,600 | $14 |
Who their Medicare patients are
136 Original Medicare patients in 2024. Average age 74 · Under 65 12% · 85 and older 9% · Women 82% · Also on Medicaid 34% · Health risk score 2.36. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 75% · Cancer 75% · Diabetes 42% · Coronary heart disease 36% · Depression 32% · Chronic kidney disease 27% · COPD 18% · Atrial fibrillation 18% · Heart failure 10% · Dementia 8%.
The office billed $210,010, Medicare allowed $64,554 and paid $49,367; for 580 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 136 | 580 | 74 | 2.36 | $210,010 | $49,367 |
| 2023 | 132 | 537 | 73 | 2.45 | $233,178 | $56,936 |
| 2022 | 77 | 366 | 73 | 1.92 | $171,152 | $39,763 |
| 2021 | 38 | 112 | 71 | 2.02 | $35,562 | $11,349 |
| 2018 | 150 | 476 | 78 | 2.71 | $206,702 | $42,615 |
| 2017 | 95 | 351 | 76 | 2.40 | $150,907 | $32,185 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Long return visit (40+ min) | 69 | $41,258 | $118 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 34 | $6,510 | $67 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,416 | $110 |
| Hospital discharge day management, more than 30 minutes | 21 | $2,544 | $98 |
2022: 3 services
| Long return visit (40+ min) | 54 | $31,833 | $123 |
| New patient visit (60+ min) | 25 | $3,932 | $157 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 20 | $1,357 | $27 |
2021: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $4,793 | $89 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $2,452 | $117 |
| Hospital discharge day management, more than 30 minutes | 17 | $1,659 | $92 |
2018: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 113 | $25,839 | $94 |
| Hospital discharge day management, more than 30 minutes | 77 | $7,703 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 49 | $6,079 | $65 |
2017: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 69 | $18,509 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $5,182 | $65 |
| Hospital discharge day management, more than 30 minutes | 46 | $4,517 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,082 | $181 |
Medicaid work
$1,877 in 2021
Medicaid paid $1,877 for 49 billed services this clinician did in 2021, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 49 | $1,877 |
| 2021 | 49 | 1 | 13 | $1,877 |
| 2018 | 208 | 2 | 22 | $4,340 |
See the largest Medicaid services in earlier years
2018
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 193 | $3,977 |
| Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter | 15 | $363 |
Drugs they prescribed that Part D paid
$65,799
Pharmacies billed $65,799 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
290 generic and 11 brand-name prescriptions · $65,799 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Exemestane | 22 | $5,462 | $248 |
| Anastrozole | 94 | $1,350 | $14 |
| Tamoxifen Citrate | 43 | $737 | $17 |
| Letrozole | 19 | $523 | $28 |
| Diclofenac | 11 | $397 | $36 |
See all 6 drugs
| Exemestane | 22 | $5,462 | $248 |
| Anastrozole | 94 | $1,350 | $14 |
| Tamoxifen Citrate | 43 | $737 | $17 |
| Letrozole | 19 | $523 | $28 |
| Diclofenac | 11 | $397 | $36 |
| Alendronate | 16 | $218 | $14 |
Year by year
| 2024 | 301 | 53 | None | 4% | $65,799 |
| 2023 | 298 | 44 | None | 14% | $303,501 |
| 2022 | 283 | 36 | None | None | $467,358 |
| 2021 | 78 | 26 | None | 27% | $199,608 |
| 2020 | 83 | 32 | 15% (12) | 24% | $210,236 |
| 2019 | 144 | 53 | 13% (18) | 19% | $120,898 |
| 2018 | 147 | 45 | None | None | $13,003 |
| 2017 | 35 | 16 | None | None | $1,257 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Ibrance | 12 | $193,598 | $16,133 |
| Exemestane | 24 | $4,100 | $171 |
| Anastrozole | 87 | $2,086 | $24 |
| Tamoxifen Citrate | 25 | $470 | $19 |
| Alendronate | 19 | $396 | $21 |
| Famotidine | 16 | $368 | $23 |
| Letrozole | 15 | $341 | $23 |
| Metoclopramide | 12 | $281 | $23 |
2022: 8 drugs
| Ibrance | 21 | $306,997 | $14,619 |
| Anastrozole | 64 | $1,581 | $25 |
| Exemestane | 11 | $1,197 | $109 |
| Olanzapine | 13 | $1,116 | $86 |
| Ondansetron | 17 | $454 | $27 |
| Gabapentin | 11 | $162 | $15 |
| Famotidine | 12 | $99 | $8 |
| Letrozole | 12 | $40 | $3 |
2019: 1 drug
| Ondansetron | 11 | $200 | $18 |
2018: 2 drugs
| Atorvastatin | 11 | $86 | $8 |
| Furosemide | 13 | $26 | $2 |
Money from drug and device companies
$29 in 2023
| 2023 | 1 | 1 | None | $29 |
| 2021 | 1 | 1 | None | $14 |
| 2020 | 7 | 7 | None | $154 |
| 2019 | 3 | 4 | None | $82 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Puma Biotechnology | None | $29 | 1 payment
|
See the published payment
| Puma Biotechnology | Meals · 2023-03-13 | None | $29 |
See earlier years (2021, 2020, 2019)
2021: $14
| Lilly USA | Retevmo | $14 | 1 payment
|
2020: $154
| Blueprint Medicines | Gavreto | $30 | 1 payment
|
| Celgene | Reblozyl | $23 | 1 payment
|
| Incyte | Jakafi | $22 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Calquence | $21 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $20 | 1 payment
|
| Merck Sharp & Dohme | None | $20 | 1 payment
|
| Jazz Pharmaceuticals | Vyxeos | $18 | 1 payment
|
2019: $82
| Amgen | Kanjinti | $49 | 2 payments
|
| Eisai | Lenvima | $17 | 1 payment
|
| Novartis Pharmaceuticals | Promacta | $16 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Janssen Research & Development, LLC · A Global, Phase 2 Study of Arx788 in Her2-Positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-Dxd · 2025 | Their institution | $116,603 |
| Janssen Research & Development, LLC · Ace-Breast-03 · 2024 | Their institution | $33,834 |
| Janssen Research & Development, LLC · Ace-Breast-O3 · 2024 | Their institution | $12,751 |
| Janssen Research & Development, LLC · Acebreast03 · 2024 | Their institution | $12,247 |
Professional record
- NPI
- 1962768671
- Licence
- CA A127648California A127648: Current · expires 2027-03-31
- Trained
- University of Michigan Medical School, 2012
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X); Hospitalist (208M00000X)
- Mailing address
- Po Box 31309, Los Angeles, CA, 90031
- NPI first listed
- 2012-04-06
- NPI last updated
- 2021-12-08
- NPI record certified
- 2021-12-08
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.